203 related articles for article (PubMed ID: 30195572)
1. Ruxolitinib for the treatment of severe alopecia areata.
Liu LY; King BA
J Am Acad Dermatol; 2019 Feb; 80(2):566-568. PubMed ID: 30195572
[No Abstract] [Full Text] [Related]
2. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
3. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis.
Putterman E; Castelo-Soccio L
J Am Acad Dermatol; 2018 Jun; 78(6):1207-1209.e1. PubMed ID: 29754888
[No Abstract] [Full Text] [Related]
4. Tofacitinib for the treatment of alopecia areata in preadolescent children.
Craiglow BG; King BA
J Am Acad Dermatol; 2019 Feb; 80(2):568-570. PubMed ID: 30195571
[No Abstract] [Full Text] [Related]
5. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata.
Lee JS; Yoon HS; Cho S; Park HS
J Dermatol; 2019 Apr; 46(4):e139-e140. PubMed ID: 30204259
[No Abstract] [Full Text] [Related]
7. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Liu LY; Craiglow BG; King BA
J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
[No Abstract] [Full Text] [Related]
8. Treatment of Alopecia Areata With Tofacitinib.
Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
[TBL] [Abstract][Full Text] [Related]
9. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
Gordon SC; Abudu M; Zancanaro P; Ko JM; Rosmarin D
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e156-e157. PubMed ID: 30520145
[No Abstract] [Full Text] [Related]
10. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
[No Abstract] [Full Text] [Related]
11. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Cheng MW; Kehl A; Worswick S; Goh C
J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
[TBL] [Abstract][Full Text] [Related]
12. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib therapy for children with severe alopecia areata.
Dai YX; Chen CC
J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
[No Abstract] [Full Text] [Related]
14. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
16. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
[No Abstract] [Full Text] [Related]
17. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
19. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).
Harris JE; Rashighi M; Nguyen N; Jabbari A; Ulerio G; Clynes R; Christiano AM; Mackay-Wiggan J
J Am Acad Dermatol; 2016 Feb; 74(2):370-1. PubMed ID: 26685721
[No Abstract] [Full Text] [Related]
20. The Good and Bad News About New Drugs for Treating Alopecia Areata.
Morgado-Carrasco D; RodrÃguez-Lobato E; Riera-Monroig J; Ferrando J
Actas Dermosifiliogr (Engl Ed); 2018; 109(1):69-70. PubMed ID: 28641742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
